Navigation Links
Alfacell Reports Fiscal Fourth Quarter and Full Year 2008 Financial Results
Date:10/14/2008

. Based on the current expected level of receipts and expenditures, the company believes that its cash and cash equivalents are sufficient to support its activities into the fourth quarter of fiscal year 2009. The company will be eligible to receive a minimum milestone payment of $20 million from its U.S. partner, Strativa Pharmaceuticals, in the event that the planned NDA submission results in the company receiving marketing approval for ONCONASE.

Clinical/Regulatory Update

Alfacell has completed patient enrollment in a confirmatory Phase IIIb clinical trial for ONCONASE in patients suffering from unresectable malignant mesothelioma (UMM) and reached the required number of evaluable events to conduct the formal statistical analyses required to complete the final sections of the ONCONASE rolling NDA. As the company has previously reported, the results of the preliminary statistical analysis of the data did not meet statistical significance for the primary endpoint of survival in UMM. However, a statistically significant improvement in survival was seen in the treatment of UMM patients who failed one prior chemotherapy regimen, a pre-defined primary data set for this sub-group of patients in the trial, which represents a currently unmet medical need. Alfacell has requested a pre-NDA meeting with the Food and Drug Administration (FDA) to discuss the details of the planned NDA submission. The company continues to estimate that the final components of the rolling NDA will be submitted by the end of 2008, and the company plans to present the results of the Phase IIIb trial at an upcoming scientific conference in 2009.

The company has completed enrollment in its Phase I clinical trials for patients suffering from non-small cell lung cancer (NSCLC) and other solid tumors and is planning for a follow-on Phase II clinical trial in NSCLC patients that exhibit resistance to platinum based chemotherapy regimens. Initiation of patient enrollment in this tria
'/>"/>

SOURCE Alfacell Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Paper in Cell Cycle Reports Alfacells ONCONASE(R) Targets siRNA
2. Alfacell Hires Advisors to Advance Strategic Alternatives
3. Alfacell Receives NASDAQ Delisting Letter
4. Alfacell Receives NASDAQ Non-Compliance Notification
5. Alfacell Reports Financial Results for Third Quarter of Fiscal 2008
6. Alfacell Announces Retirement of Chief Executive Officer
7. Alfacell Reports Financial Results for Second Quarter of Fiscal 2008
8. Alfacell to Host Fiscal Second Quarter 2008 Financial Results Conference Call and Webcast
9. Alfacell Announces ONCONASE(R) Purchase and Supply Agreement with Scientific Protein Laboratories
10. Alfacell to Host Webinar on RNA Interference-Like Mechanics of RNase Therapeutics on Nov. 29
11. Alfacell to Host Fiscal Fourth Quarter and Year-End 2007 Financial Results Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2015)... 23, 2015 Six startups from ... April 4-17 as part of the U.S.-Russia Innovation ... group of biotechnology startups to participate in the ... (UNN) and the University of Maryland (UMD) signed ... their respective universities in the biomedical industry in ...
(Date:4/23/2015)... 2015  Cryoport, Inc. (OTCBB: CYRX) ("Company"), the ... the life sciences industry, today announced that the ... within the animal husbandry market by signing a ... the shipment of equine semen for artificial insemination ... Animal husbandry is a multi-billion dollar ...
(Date:4/23/2015)... Irvine, CA (PRWEB) April 23, 2015 ... research leader in Personalized Medicine, is excited to ... Medication Response profile . This profile assesses 62 ... and provide dosing information for commonly prescribed non-opioid ... gabapentin (brand name Neurontin), alprazolam (brand name Xanax) ...
(Date:4/23/2015)... ReliantHeart's HeartAssist5® Ventricular Assist Device (VAD) ... the device) in real time, and this data is ... provider of Machine to Machine (M2M) communications for the ... VADLink.com can be monitored by a patient’s ... flow below a minimum threshold, the patient can be ...
Breaking Biology Technology:U.S.-Russian Innovation Corridor Program Connects Visiting Russian Startups to U.S. Experts 2U.S.-Russian Innovation Corridor Program Connects Visiting Russian Startups to U.S. Experts 3U.S.-Russian Innovation Corridor Program Connects Visiting Russian Startups to U.S. Experts 4Cryoport to Support the Equine Animal Husbandry Market Through Agreement with Yancey Farms 2Cryoport to Support the Equine Animal Husbandry Market Through Agreement with Yancey Farms 3Proove Biosciences Launches World’s First Test to Predict Responders to Commonly Prescribed Non-Opioid Pain Medications 2Proove Biosciences Launches World’s First Test to Predict Responders to Commonly Prescribed Non-Opioid Pain Medications 3
... 3SBio Inc.,(Nasdaq: SSRX ) ("3SBio" or ... focused on researching, developing, manufacturing and,marketing biopharmaceutical ... board of directors has approved a share ... 3SBio to purchase up to US$20 million ...
... Genomas(R), a,biomedical company advancing DNA-guided medicine and ... Phase I-II Small,Business Innovation Research (SBIR) Grant totaling ... Statin Safety and Efficacy," was,awarded by the National ... are the most prescribed drugs in the world. ...
... to Attend April Meeting,in St. Louis, DANBURY, ... (SBS) today announced its outstanding roster of,keynote speakers ... be held,April 6-10 at America,s Center in St. ... and biotech industries from around the world are,expected ...
Cached Biology Technology:3SBio Inc. Approves Share Repurchase Program 2Genomas Awarded $1.2 Million NIH SBIR Grant to Develop DNA-Guided System for Management of Statin Therapy 2Society for Biomolecular Sciences Announces 2008 Conference Speaker Line-up 2
(Date:3/23/2015)... , March 23, 2015  In the 2014 fiscal ... case conviction losses. This figure accounts for a fraction ... to The Nilson Report, exceeds $11 billion globally. The ... after a crime has occurred. Investor Mark Saint ... expert Joe Paolella partnered to administer the ...
(Date:3/20/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... growing mobile commerce market, announces its biometric payment technology, ... featured in 2015 "I Want That" International CES Special, ... the DIY Network.   DIY,s "I Want ... site of the 2015 International CES for a firsthand ...
(Date:3/17/2015)... , March 17, 2015 ... company specializing in clinical study management systems, is ... in attendance at ARENA,s Outsourcing in Clinical Trials ... This event provides an excellent forum for MedNet ... flexible and affordable software-as-a-service (SaaS) eClinical technology platform. ...
Breaking Biology News(10 mins):Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 2NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 3Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2
... PITTSBURGHCarnegie Mellon University,s John Kitchin was awarded $750,000 ... of Energy for developing new materials for producing ... was elated to hear that my research had been ... professor in Chemical Engineering at Carnegie Mellon. "This ...
... distinctive red soils could play a part in the formation ... off east coast beaches in summer., A QUT team of ... gives our iron-rich soil its red colour, reaches water to ... a foul smell, but also make our eyes sting, cause ...
... This release is available in German . ... decreased over recent decades. In fact, the number of beekeepers has ... the result of a study that has now been published by ... provided an overview of the problem of bee colony decline at ...
Cached Biology News:Carnegie Mellon's John Kitchin receives early career award 2Is iron from soil a factor in algal blooms? 2Fewer honey bee colonies and beekeepers throughout Europe 2Fewer honey bee colonies and beekeepers throughout Europe 3
Mouse monoclonal antibody to ALAS2 - aminolevulinate, delta-, synthase 2 (sideroblastic/hypochromic anemia)...
Mouse monoclonal antibody raised against a partial recombinant FBXO24. NCBI Entrez Gene ID = FBXO24...
Mouse monoclonal antibody raised against a partial recombinant CALCOCO2. NCBI Entrez Gene ID = CALCOCO2...
Mouse monoclonal to Casein Kinase 2 beta ( Abpromise for all tested applications). entrezGeneID: 1460 SwissProtID: P13862...
Biology Products: